{
    "organizations": [],
    "uuid": "e56cf736d8377de5525a47ff25047f50f0c85179",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-calithera-biosciences-announces-fd/brief-calithera-biosciences-announces-fda-fast-track-designation-granted-to-cb-839-in-combination-with-cabozantinib-for-treatment-of-patients-with-advanced-renal-cell-carcinoma-idUSASC09W9A",
    "ord_in_thread": 0,
    "title": "BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - Calithera Biosciences Inc:\n* CALITHERA BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO CB-839 IN COMBINATION WITH CABOZANTINIB FOR TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-18T19:25:00.000+03:00",
    "crawled": "2018-04-19T14:43:02.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "calithera",
        "bioscience",
        "inc",
        "calithera",
        "bioscience",
        "announces",
        "fda",
        "fast",
        "track",
        "designation",
        "granted",
        "combination",
        "cabozantinib",
        "treatment",
        "patient",
        "advanced",
        "renal",
        "cell",
        "carcinoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}